期刊
JOURNAL OF CONTROLLED RELEASE
卷 244, 期 -, 页码 314-325出版社
ELSEVIER
DOI: 10.1016/j.jconrel.2016.07.012
关键词
Nanomedicine; Drug targeting; Polymeric micelles; Core-crosslinking; Drug release
资金
- Cristal Therapeutics
To optimally exploit the potential of (tumor-) targeted nanomedicines, platform technologies are needed in which physicochemical and pharmaceutical properties can be tailored according to specific medical needs and applications. We here systematically customized the properties of core-crosslinked polymeric micelles (CCPM). The micelles were based on mPEG-b-pHPMAmLac(n) (i.e. methoxy poly(ethylene glycol)-b-poly[ N-(2-hydroxypropyl) methacrylamide-lactate]), similar to the block copolymer composition employed in CriPec (R) docetaxel, which is currently in phase I clinical trials. The CCPM platform was tailored with regard to size (30 to 100 nm), nanocarrier degradation (1 month to 1 year) and drug release kinetics (10 to 90% in 1 week). This was achieved by modulating the molecular weight of the block copolymer, the type and density of the crosslinking agent, and the hydrolytic sensitivity of the drug linkage, respectively. The high flexibility of CCPM facilitates the development of nanomedicinal products for specific therapeutic applications. (C) 2016 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据